Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apnimed, Inc.APMD · Entity 4910 | Director | July 30, 2026 | August 03, 2026 |
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | May 14, 2026 | May 18, 2026 |
| Nabriva Therapeutics Legacy plcNBRV · Entity 174291 | Chief Financial Officer | June 23, 2017 | June 28, 2017 |
| Nabriva Therapeutics plcNBRV · Entity 111497 | Chief Financial Officer | February 28, 2021 | March 02, 2021 |
| Schrodinger, Inc.SDGR · Entity 4667 | Director | June 22, 2026 | June 23, 2026 |
| iBio, Inc.IBIO · Entity 6906 | Director | November 20, 2025 | November 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apnimed, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2034-12-12 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Disposition to issuer · Disposed 51,890 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2034-12-12 | Direct | 51,890 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 51,890 · Balance 51,890 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07 | Direct | 44,477 |
Reported balance
After 2026-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-30 · Grant · Acquired 44,477 · Balance 44,477 F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-08-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date
Harmony Biosciences Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14 | Direct | 21,872 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 21,872 · Balance 21,872 F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Nabriva Therapeutics Legacy plc
Report date June 23, 2017 · Filed June 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,200 |
Reported balance
After 2017-06-23 transaction · row 1
1 source rowRow 1 · 2017-06-23 · Other · Acquired 2,200 · Balance 2,200 F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2026-05-30 | Direct | 88,800 |
Reported balance
After 2017-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-23 · Other · Acquired 88,800 · Balance 88,800 F2: The exercise price is 6.50 Euro. F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3: This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2027-02-06 | Direct | 113,000 |
Reported balance
After 2017-06-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-23 · Other · Acquired 113,000 · Balance 113,000 F4: The exercise price is 7.963 Euro. F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5: This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
F2: The exercise price is 6.50 Euro.
F3: This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
F4: The exercise price is 7.963 Euro.
F5: This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.
Nabriva Therapeutics plc
Report date February 28, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,472 |
Reported balance
After 2021-02-28 transaction · row 1
1 source rowRow 1 · 2021-02-28 · Tax withholding · Disposed 31 · Balance 20,472 F1: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.
Schrodinger, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,388 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 8,141 · Balance 25,388 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2: Includes 8,141 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2036-06-22 | Direct | 13,313 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 13,313 · Balance 13,313 F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service.
F2: Includes 8,141 unvested RSUs.
F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service.
iBio, Inc.
Report date November 20, 2025 · Filed November 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-11-19 | Direct | 13,500 |
Reported balance
After 2025-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-20 · Grant · Acquired 13,500 · Balance 13,500 F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330504 · ownership.xml · derivative · entry 7 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,477 Underlying: Common Stock · 44,477 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330504 · ownership.xml · derivative · entry 6 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 44,477 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330504 · ownership.xml · derivative · entry 4 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,477 Underlying: Common Stock · 44,477 shares Expires 2036-07-07 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330504 · ownership.xml · derivative · entry 3 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 44,477 shares Expires 2036-07-07 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 51,890 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001193125-26-330504 · ownership.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,890 Underlying: Common Stock · 51,890 shares Expires 2034-12-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 51,890 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001193125-26-330504 · ownership.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 51,890 shares Expires 2034-12-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330504 · ownership.xml · derivative · entry 5 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,477 Underlying: Class A Common Stock · 44,477 shares Expires 2036-07-29 F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:29 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 13,313 | $0.00 Strike: $15.23 | $0.00 |
DisclosureSEC source: 0001659085-26-000003 · wk-form4_1782246543.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,313 Underlying: Common Stock · 13,313 shares Expires 2036-06-22 F3 · derivative.exercise_date: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:29 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 8,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001659085-26-000003 · wk-form4_1782246543.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,388 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2 · balance_after: Includes 8,141 unvested RSUs. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 21,872 | $0.00 Strike: $30.76 | $0.00 |
DisclosureSEC source: 0001659085-26-000002 · form4-05182026_080548.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,872 Underlying: Common Stock · 21,872 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:08 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-25-115410 · tm2532045-4_4seq1.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-11-19 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:36 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 9,341 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001490978-25-000091 · wk-form4_1750451757.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,341 Underlying: Common Stock · 9,341 shares Expires 2035-06-18 F3 · derivative.exercise_date: The option was granted on June 18, 2025 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:36 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 5,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001490978-25-000091 · wk-form4_1750451757.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,247 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2025 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2 · balance_after: Includes 5,997 unvested RSUs. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:01 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 14,522 | $0.00 Strike: $34.23 | $0.00 |
DisclosureSEC source: 0001415889-25-013397 · form4-05162025_080517.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,522 Underlying: Common Stock · 14,522 shares Expires 2035-05-15 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 15, 2026 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:30 UTC | iBio, Inc. IBIO · Entity 6906 | PurchaseCommon Stock | 9,191 | $2.72 | $24,999.52 |
DisclosureSEC source: 0001104659-25-003058 · tm253156-1_4seq1.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,191 F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:34 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-122595 · tm2429436-6_4seq1.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2034-11-20 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:19 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 8,550 | $0.00 Strike: $19.32 | $0.00 |
DisclosureSEC source: 0001490978-24-000057 · wk-form4_1718914747.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,550 Underlying: Common Stock · 8,550 shares Expires 2034-06-18 F3 · derivative.exercise_date: The option was granted on June 18, 2024. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:19 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001490978-24-000057 · wk-form4_1718914747.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2024 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2 · balance_after: Includes 5,000 unvested RSUs. Read SEC document |
| May 29, 2024 Filed May 31, 2024 12:58 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 11,657 | $0.00 Strike: $29.33 | $0.00 |
DisclosureSEC source: 0001415889-24-014970 · form4-05312024_120500.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,657 Underlying: Common Stock · 11,657 shares Expires 2034-05-29 F1 · derivative.exercise_date: 1. The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:56 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $45.26 | $0.00 |
DisclosureSEC source: 0001490978-23-000076 · wk-form4_1686948952.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-15 F3 · derivative.exercise_date: The option was granted on June 15, 2023. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:56 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001490978-23-000076 · wk-form4_1686948952.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 15, 2023 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2 · balance_after: Includes 6,250 unvested RSUs. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:35 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 9,613 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001415889-23-008856 · form4-05262023_040502.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,255 Underlying: Common Stock · 9,613 shares Expires 2033-05-25 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 25, 2024 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:00 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 14,907 | $0.00 Strike: $24.51 | $0.00 |
DisclosureSEC source: 0001209191-22-037485 · doc4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,907 Underlying: Common Stock · 14,907 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option was granted on June 15, 2022. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:18 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 8,726 | $0.00 Strike: $41.33 | $0.00 |
DisclosureSEC source: 0001104659-22-064252 · tm2216688-5_4seq1.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,726 Underlying: Common Stock · 8,726 shares Expires 2032-05-20 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 20, 2023 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 23:58 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001104659-21-149222 · tm2135158-3_4seq1.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2031-12-08 F1 · security: These options vest pro rata on a monthly basis over 12 months. F1 · shares: These options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:01 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 8,736 | $0.00 Strike: $76.08 | $0.00 |
DisclosureSEC source: 0001209191-21-042100 · doc4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,736 Underlying: Common Stock · 8,736 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option was granted on June 17, 2021. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| May 20, 2021 Filed Jun 14, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 13,333 | $0.00 Strike: $32.50 | $0.00 |
DisclosureSEC source: 0000899243-21-023567 · doc4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2031-05-20 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 20, 2022 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 23:18 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 12,890 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019596 · doc4.xml · derivative · entry 5 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19 Underlying: Common Stock · 12,890 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on February 5, 2020 and is fully vested. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 23:18 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 15,885 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001209191-21-019596 · doc4.xml · derivative · entry 4 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,246 Underlying: Common Stock · 15,885 shares Expires 2029-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on August 1, 2019. The shares underlying the option vested with respect to 25% of the shares on July 22, 2020 and the remainder are scheduled to vest in equal monthly installments through July 22, 2023. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 23:18 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 28,775 | $66.55 | $1,914,838.13 |
DisclosureSEC source: 0001209191-21-019596 · doc4.xml · nonDerivative · entry 3 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.50 to $66.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 23:18 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 12,890 | $17.00 | $219,130.00 |
DisclosureSEC source: 0001209191-21-019596 · doc4.xml · nonDerivative · entry 2 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 23:18 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 15,885 | $5.31 | $84,349.35 |
DisclosureSEC source: 0001209191-21-019596 · doc4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 19:43 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 31 | $2.39 | $74.09 |
DisclosureSEC source: 0001104659-21-030950 · tm218516-5_4seq1.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,472 F1 · shares: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 20:01 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 37 | $2.62 | $96.94 |
DisclosureSEC source: 0001104659-21-011108 · tm215099-5_4seq1.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,503 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 17:16 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 32 | $2.42 | $77.44 |
DisclosureSEC source: 0001104659-21-001044 · tm211621-5_4seq1.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,540 F1 · balance_after: The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 20:22 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 312 | $0.43 | $133.22 |
DisclosureSEC source: 0001104659-20-131223 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,728 Read SEC document |
| October 31, 2020 Filed Nov 2, 2020 19:07 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 312 | $0.50 | $154.60 |
DisclosureSEC source: 0001104659-20-120642 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,040 Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 10:08 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001104659-20-115456 · tm2033244d4_form4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-10-13 F1 · shares: These options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 16:32 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 312 | $0.53 | $166.30 |
DisclosureSEC source: 0001104659-20-111080 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,352 Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 17:16 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 312 | $0.62 | $193.25 |
DisclosureSEC source: 0001104659-20-101909 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,664 Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 19:02 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 3,204 | $0.65 | $2,074.91 |
DisclosureSEC source: 0001104659-20-097716 · a4.xml · nonDerivative · entry 2 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,976 Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 19:02 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Exercise / conversionRestricted Share Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-097716 · a4.xml · derivative · entry 3 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 22,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition. F2 · derivative.expiration_date: On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 22,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 19:02 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Exercise / conversionOrdinary Shares | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-097716 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 23:59 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 16,583 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023121 · doc4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,583 Underlying: Common Stock · 16,583 shares Expires 2030-08-18 F1 · derivative.exercise_date: The stock option shall vest in three equal annual installments beginning on August 21, 2021. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:07 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 312 | $0.76 | $237.12 |
DisclosureSEC source: 0001104659-20-090278 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,930 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:06 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 312 | $0.67 | $210.48 |
DisclosureSEC source: 0001104659-20-080539 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,242 Read SEC document |
| May 31, 2020 Filed Jun 3, 2020 06:08 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 312 | $1.14 | $355.68 |
DisclosureSEC source: 0001104659-20-069188 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,554 F1 · balance_after: The total reported in Column 5 includes 6,187 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan ("ESPP") on May 29, 2020. Read SEC document |
| April 30, 2020 Filed May 4, 2020 18:32 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 301 | $0.55 | $165.04 |
DisclosureSEC source: 0001104659-20-056352 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,679 Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 17:49 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 301 | $0.58 | $173.08 |
DisclosureSEC source: 0001104659-20-042582 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,980 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:32 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 301 | $1.35 | $406.35 |
DisclosureSEC source: 0001104659-20-028850 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,281 F1 · balance_after: The total reported in Column 5 includes 5,154 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan ("ESPP") on April 30, 2019 and 5,759 shares acquired under the ESPP on October 31, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.